Use of Campath [alemtuzumab] for induction and maintenance therapy in pancreas after kidney transplantation.

Trial Profile

Use of Campath [alemtuzumab] for induction and maintenance therapy in pancreas after kidney transplantation.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 15 Dec 2009

At a glance

  • Drugs Alemtuzumab; Antithymocyte globulin; Mycophenolate mofetil; Tacrolimus
  • Indications Kidney-pancreas transplant rejection
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Dec 2009 Actual number of patients (9) added as reported by ClinicalTrials.gov record.
    • 25 Sep 2007 The expected completion date for this trial is now 1 Nov 2006.
    • 10 Sep 2007 Status changed from in progress to discontinued.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top